Age and duration of testosterone therapy predict time to return of sperm count after human chorionic gonadotropin therapy
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Objective To determine factors that influence sperm recovery after testosterone-associated infertility. Design Clinical retrospective study. Setting Academic male-infertility urology clinic. Patient(s) Sixty-six men who presented with infertility after testosterone use. Intervention(s) Testosterone (T) cessation and combination high-dose human chorionic gonadotropin (hCG) and selective estrogen modulator (SERM) therapy. Main Outcome Measure(s) Whether patients successfully achieved or failed to achieve a total motile count (TMC) of greater than 5 million sperm within 12 months of T cessation and initiation of therapy. Result(s) A TMC of greater than 5 million sperm was achieved by 46 men (70%). Both increased age and duration of testosterone use directly correlated with time to sperm recovery at both 6 and 12 months of hCG/SERM therapy. Age more consistently limited sperm recovery, while duration of testosterone use had less influence at 12 months than at 6 months. Only 64.8% of azoospermic men achieved a TMC greater than 5 million sperm at 12 months, compared with 91.7% of cryptozoospermic men, yet this did not predict a failure of sperm recovery. Conclusion(s) Increasing age and duration of testosterone use significantly reduce the likelihood of recovery of sperm in the ejaculate, based on a criterion of a TMC of 5 million sperm, at 6 and 12 months. Physicians should be cautious in pursuing long-term testosterone therapy, particularly in men who still desire fertility. Using these findings, physicians can counsel men regarding the likelihood of recovery of sperm at 6 and 12 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men
Harman, S. M., Metter, E. J., Tobin, J. D., Pearson, J., & Blackman, M. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7219 · Cited by 2,760
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Liu, P. Y., Swerdloff, R. S., Christenson, P. D., Handelsman, D. J., & Wang, C. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68614-5 · Cited by 272
Coviello, A. D., Matsumoto, A. M., Bremner, W. J., Herbst, K. L., Amory, J. K., Anawalt, B. D., Sutton, P. R., Wright, W. W., Brown, T. R., Yan, X., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0802 · Cited by 154
The Use of HCG-Based Combination Therapy for Recovery of Spermatogenesis after Testosterone Use
Wenker, E. P., Dupree, J. M., Langille, G. M., Kovac, J., Ramasamy, R., Lamb, D., Mills, J. N., & Lipshultz, L. I. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12890 · Cited by 101
Self-citationTestosterone Suppression of the HPT Axis
MacIndoe, J. H., Perry, P. J., Yates, W. R., Holman, T. L., Ellingrod, V. L., & Scott, S. D. (1997) · Journal of Investigative Medicine · doi:10.1177/108155899704500808 · Cited by 59
Research works printed but not linked: 18
- McKinlay, 2007, Measuring the urologic iceberg: design and implementation of the Boston Area Community Health (BACH) Survey, Eur Urol, 52, 389, 10.1016/j.eururo.2007.03.013 · DOI
- Nguyen, 2015, Testosterone and “age-related hypogonadism”—FDA concerns, N Eng J Med, 373, 689, 10.1056/NEJMp1506632 · DOI · Paper page
- Layton, 2014, Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011, J Clin Endocrinol Metab, 99, 835, 10.1210/jc.2013-3570 · DOI · Paper page
- Kolettis, 2015, Medical testosterone: an iatrogenic cause of male infertility and a growing problem, Urology, 85, 1068, 10.1016/j.urology.2014.12.052 · DOI
- Ko, 2012, Empirical medical therapy for idiopathic male infertility: a survey of the American Urological Association, J Urol, 187, 973, 10.1016/j.juro.2011.10.137 · DOI · Paper page
- McBride, 2016, Recovery of spermatogenesis following testosterone replacement therapy or anabolic-androgenic steroid use, Asian J Androl, 18, 373, 10.4103/1008-682X.173938 · DOI
- Ly, 2005, Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens, Hum Reprod, 20, 1733, 10.1093/humrep/deh834 · DOI · Paper page
- Menon, 2003, Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin, Fertil Steril, 79, 1659, 10.1016/S0015-0282(03)00365-0 · DOI
- Liu, 1999, Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men, Hum Reprod, 14, 1540, 10.1093/humrep/14.6.1540 · DOI · Paper page
- Coward, 2014, Vasectomy reversal outcomes in men previously on testosterone supplementation therapy, Urology, 84, 1335, 10.1016/j.urology.2014.06.081 · DOI
- Rahnema, 2014, Anabolic steroid-induced hypogonadism: diagnosis and treatment, Fertil Steril, 101, 1271, 10.1016/j.fertnstert.2014.02.002 · DOI · Paper page
- Ishikawa, 2007, Assessment of gonadotropin therapy in male hypogonadotropic hypogonadism, Fertil Steril, 88, 1697, 10.1016/j.fertnstert.2006.11.022 · DOI
- Gill, 1998, Anabolic steroid induced hypogonadism treated with human chorionic gonadotropin, Postgrad Med J, 74, 45, 10.1136/pgmj.74.867.45 · DOI
- Hay, 2005, A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception, J Clin Endocrinol Metab, 90, 2042, 10.1210/jc.2004-0895 · DOI · Paper page
- Kinniburgh, 2002, Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men, Hum Reprod, 17, 1490, 10.1093/humrep/17.6.1490 · DOI · Paper page
- Amory, 2001, Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development, J Androl, 22, 1053, 10.1002/j.1939-4640.2001.tb03445.x · DOI · Paper page
- Turner, 2003, Contraceptive efficacy of a depot progestin and androgen combination in men, J Clin Endocrinol Metab, 88, 4659, 10.1210/jc.2003-030107 · DOI · Paper page
- World Health Organization Task Force on Methods for the Regulations of Male Fertility, 1995, Rates of testosterone-induced suppression to severe oligozoospermia or azoospermia in two multinational clinical studies, Int J Androl, 18, 157, 10.1111/j.1365-2605.1995.tb00405.x · DOI
Cited by
Eisenberg, M. L., Esteves, S. C., Lamb, D. J., Hotaling, J. M., Giwercman, A., Hwang, K., & Cheng, Y.-S. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00459-w · Cited by 536
The Dynamic Transcriptional Cell Atlas of Testis Development during Human Puberty
Guo, J., Nie, X., Giebler, M., Mlcochova, H., Wang, Y., Grow, E. J., Kim, R., Tharmalingam, M., Matilionyte, G., Lindskog, C., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.12.005 · Cited by 315
Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications
Solomon, Z. J., Mirabal, J. R., Mazur, D. J., Kohn, T. P., Lipshultz, L. I., & Pastuszak, A. W. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.09.006 · Cited by 174
“Exogenous testosterone interferes with spermatogenesis via negative feedback on the hypothalamicpituitary-gonadal axis.[11,22] Chen et al.”
BackgroundSelf-citationKasman, A. M., Del Giudice, F., & Eisenberg, M. L. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.01.002 · Cited by 94
“A cohort study of 66 men with prior testosterone therapy examined their recovery rate (defined as total motile count >5 million sperm) at 12 months after cessation of the testosterone therapy and treatment with human chorionic gonadotropin or selective estrogen receptor modulators (67).”
MethodTatem, A. J., Beilan, J., Kovac, J. R., & Lipshultz, L. I. (2020) · The World Journal of Men's Health · doi:10.5534/wjmh.190002 · Cited by 66
“Kohn et al [25] showed that both advanced age and increased duration of TTh have negative effects on time to recovery of spermatogenesis.”
BackgroundSelf-citationFrontiers in hormone therapy for male infertility
Khourdaji, I., Lee, H., & Smith, R. P. (2018) · Translational Andrology and Urology · doi:10.21037/tau.2018.04.03 · Cited by 47
Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review.
Raheem, O. A., Chen, T., Akula, K. P., Greenberg, J., Le, T. V., Chernobylsky, D., Sikka, S. C., & Walsh, T. J. (2021) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.08.003 · Cited by 22
Song, S.-H., Sung, S., Her, Y. S., Oh, M., Shin, D. H., Lee, J., Baek, J., Lee, W. S., & Kim, D. S. (2019) · Clinical and Experimental Reproductive Medicine · doi:10.5653/cerm.2019.00290 · Cited by 14
Metadata
- Authors
- Kohn, T. P., Louis, M. R., Pickett, S. M., Lindgren, M. C., Kohn, J. R., Pastuszak, A. W., & Lipshultz, L. I.
- Venue
- Fertility and Sterility
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 107
- Issue
- 2
- Pages
- 351-357.e1
- ISSN
- 0015-0282 (ISSN-L)
- OpenAlex
- W2556419258
- Cited by
- 67
- References
- 6
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 1941 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.